Catalyst Biosciences (CBIO) Reports Q2 Loss of $0.42/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Catalyst Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 4, 2016 8:31 AM EDT-- Phase 1 Proof-of-Concept Clinical Trial of High Potency Factor IX Product Subcutaneous Administration for Hemophilia B to Commence in the First Quarter 2017 --
-- Manufacturing Agreement Established for CB 813d, Next-Generation Factor VIIa Product, in Preparation for a Trial of Subcutaneous Prophylaxis in Hemophilia A and B Inhibitor Patients to Commence in 2017Â --
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Â Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biotechnology company focused on creating and developing novel protease therapeutics to treat serious medical conditions in the fields of hemostasis... More
